Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 45


Forty years of research on xeroderma pigmentosum at the US National Institutes of Health.

Kraemer KH, DiGiovanna JJ.

Photochem Photobiol. 2015 Mar-Apr;91(2):452-9. doi: 10.1111/php.12345. Epub 2015 Jan 8. Review.


Updated Physician's Guide to the Off-label Uses of Oral Isotretinoin.

Nickle SB, Peterson N, Peterson M.

J Clin Aesthet Dermatol. 2014 Apr;7(4):22-34. Review.


Xeroderma pigmentosum: man deprived of his right to light.

Mareddy S, Reddy J, Babu S, Balan P.

ScientificWorldJournal. 2013 Dec 29;2013:534752. doi: 10.1155/2013/534752. eCollection 2013. Review.


Tazarotene: randomized, double-blind, vehicle-controlled, and open-label concurrent trials for basal cell carcinoma prevention and therapy in patients with basal cell nevus syndrome.

Tang JY, Chiou AS, Mackay-Wiggan JM, Aszterbaum M, Chanana AM, Lee W, Lindgren JA, Raphael MA, Thompson BJ, Bickers DR, Epstein EH Jr.

Cancer Prev Res (Phila). 2014 Mar;7(3):292-9. doi: 10.1158/1940-6207.CAPR-13-0305. Epub 2014 Jan 17.


Headway and hurdles in the clinical development of dietary phytochemicals for cancer therapy and prevention: lessons learned from vitamin A derivatives.

Yim CY, Mao P, Spinella MJ.

AAPS J. 2014 Mar;16(2):281-8. doi: 10.1208/s12248-014-9562-2. Epub 2014 Jan 16. Review.


The influence of DNA repair on neurological degeneration, cachexia, skin cancer and internal neoplasms: autopsy report of four xeroderma pigmentosum patients (XP-A, XP-C and XP-D).

Lai JP, Liu YC, Alimchandani M, Liu Q, Aung PP, Matsuda K, Lee CC, Tsokos M, Hewitt S, Rushing EJ, Tamura D, Levens DL, Digiovanna JJ, Fine HA, Patronas N, Khan SG, Kleiner DE, Oberholtzer JC, Quezado MM, Kraemer KH.

Acta Neuropathol Commun. 2013 May 8;1:4. doi: 10.1186/2051-5960-1-4.


Retinoids for prevention and treatment of actinic keratosis.

Ianhez M, Fleury LF Jr, Miot HA, Bagatin E.

An Bras Dermatol. 2013 Jul-Aug;88(4):585-93. doi: 10.1590/abd1806-4841.20131803. Review.


Age-associated decreases in human DNA repair capacity: Implications for the skin.

Hadshiew IM, Eller MS, Gilchrest BA.

Age (Omaha). 1999 Apr;22(2):45-57. doi: 10.1007/s11357-999-0006-3.


Abnormal XPD-induced nuclear receptor transactivation in DNA repair disorders: trichothiodystrophy and xeroderma pigmentosum.

Zhou X, Khan SG, Tamura D, Ueda T, Boyle J, Compe E, Egly JM, DiGiovanna JJ, Kraemer KH.

Eur J Hum Genet. 2013 Aug;21(8):831-7. doi: 10.1038/ejhg.2012.246. Epub 2012 Dec 12.


Difluoromethylornithine: the proof is in the polyamines.

Jeter JM, Alberts DS.

Cancer Prev Res (Phila). 2012 Dec;5(12):1341-4. doi: 10.1158/1940-6207.CAPR-12-0429.


Shining a light on xeroderma pigmentosum.

DiGiovanna JJ, Kraemer KH.

J Invest Dermatol. 2012 Mar;132(3 Pt 2):785-96. doi: 10.1038/jid.2011.426. Epub 2012 Jan 5. Review.


Isotretinoin and FoxO1: A scientific hypothesis.

Melnik BC.

Dermatoendocrinol. 2011 Jul;3(3):141-65. doi: 10.4161/derm.3.3.15331. Epub 2011 Jul 1.


The retinoid signalling molecule, TRIM16, is repressed during squamous cell carcinoma skin carcinogenesis in vivo and reduces skin cancer cell migration in vitro.

Cheung BB, Koach J, Tan O, Kim P, Bell JL, D'andreti C, Sutton S, Malyukova A, Sekyere E, Norris M, Haber M, Kavallaris M, Cunningham AM, Proby C, Leigh I, Wilmott JS, Cooper CL, Halliday GM, Scolyer RA, Marshall GM.

J Pathol. 2012 Feb;226(3):451-62. doi: 10.1002/path.2986. Epub 2011 Oct 18.


Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251).

Kadakia KC, Barton DL, Loprinzi CL, Sloan JA, Otley CC, Diekmann BB, Novotny PJ, Alberts SR, Limburg PJ, Pittelkow MR.

Cancer. 2012 Apr 15;118(8):2128-37. doi: 10.1002/cncr.26374. Epub 2011 Aug 31.


Therapeutic prevention of colorectal carcinogenesis.

Meyskens FL Jr.

J Carcinog. 2011;10:13. doi: 10.4103/1477-3163.79682. Epub 2011 Apr 16. No abstract available.


Ophthalmic manifestations and histopathology of xeroderma pigmentosum: two clinicopathological cases and a review of the literature.

Ramkumar HL, Brooks BP, Cao X, Tamura D, Digiovanna JJ, Kraemer KH, Chan CC.

Surv Ophthalmol. 2011 Jul-Aug;56(4):348-61. doi: 10.1016/j.survophthal.2011.03.001. Review.


New agents for prevention of ultraviolet-induced nonmelanoma skin cancer.

Camp WL, Turnham JW, Athar M, Elmets CA.

Semin Cutan Med Surg. 2011 Mar;30(1):6-13. doi: 10.1016/j.sder.2011.01.003.


Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial.

Elmets CA, Viner JL, Pentland AP, Cantrell W, Lin HY, Bailey H, Kang S, Linden KG, Heffernan M, Duvic M, Richmond E, Elewski BE, Umar A, Bell W, Gordon GB.

J Natl Cancer Inst. 2010 Dec 15;102(24):1835-44. doi: 10.1093/jnci/djq442. Epub 2010 Nov 29.


Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterises the role of DNA repair.

Bradford PT, Goldstein AM, Tamura D, Khan SG, Ueda T, Boyle J, Oh KS, Imoto K, Inui H, Moriwaki S, Emmert S, Pike KM, Raziuddin A, Plona TM, DiGiovanna JJ, Tucker MA, Kraemer KH.

J Med Genet. 2011 Mar;48(3):168-76. doi: 10.1136/jmg.2010.083022. Epub 2010 Nov 19.


Dose response of retinol and isotretinoin in the prevention of nonmelanoma skin cancer recurrence.

Clouser MC, Roe DJ, Foote JA, Harris RB, Alberts DS.

Nutr Cancer. 2010;62(8):1058-66. doi: 10.1080/01635581.2010.492089.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk